dc.contributor
Institut Català de la Salut
dc.contributor
[Muñoz Couselo E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Berking C] Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Comprehensive Cancer Center Erlangen—European Metropolitan Area of Nürnberg (CCC ER-EMN), Erlangen, Germany. Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Erlangen, Germany. [Baurain JF] Institut Roi Albert II, Cliniques Universitaires SaintLuc, Université Catholique de Louvain, Brussels, Belgium. Institute for Experimental and Clinical Research, Université Catholique de Louvain, Brussels, Belgium. [Martelli S, Arntz R] Sun Pharmaceutical Industries B.V., Hoofddorp, The Netherlands. [Savoia P] Department of Health Sciences, University of Eastern Piedmont, Novara, Italy
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
BAURAIN, JEAN-FRANCOIS
dc.contributor.author
Martelli, Serena
dc.contributor.author
Arntz, Ramon
dc.contributor.author
Savoia, Paola
dc.contributor.author
MUÑOZ COUSELO, EVA
dc.contributor.author
Berking, Carola
dc.date.accessioned
2025-09-30T02:07:32Z
dc.date.available
2025-09-30T02:07:32Z
dc.date.issued
2025-09-19T08:25:45Z
dc.date.issued
2025-09-19T08:25:45Z
dc.identifier
Muñoz Couselo E, Berking C, Baurain JF, Martelli S, Arntz R, Savoia P. Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma. J Eur Acad Dermatology Venereol. 2025 Sep;39(9):e788–90.
dc.identifier
http://hdl.handle.net/11351/13689
dc.identifier
10.1111/jdv.20629
dc.identifier
001439777700001
dc.identifier.uri
https://hdl.handle.net/11351/13689
dc.description.abstract
Secondary resistance; Locally advanced basal cell carcinoma
dc.description.abstract
Resistencia secundaria; Carcinoma basocelular localmente avanzado
dc.description.abstract
Resistència secundària; Carcinoma basocel·lular localment avançat
dc.description.abstract
The BOLT study was sponsored and funded by Novartis; this analysis was funded by Sun Pharma. Medical writing and editorial support were funded by Sun Pharma Europe B.V.
dc.format
application/pdf
dc.relation
Journal of the European Academy of Dermatology and Venereology;39(9)
dc.relation
https://doi.org/10.1111/jdv.20629
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Medicaments antineoplàstics - Ús terapèutic - Efectes secundaris
dc.subject
Carcinoma basocel·lular - Tractament
dc.subject
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Carcinoma, Basal Cell
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
dc.subject
Other subheadings::Other subheadings::Other subheadings::/adverse effects
dc.subject
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::carcinoma basocelular
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
dc.title
Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
